Loncar China BioPharma ETF
CHNA
CHNA was delisted on the 20th of October, 2023.
6 hedge funds and large institutions have $1.9M invested in Loncar China BioPharma ETF in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 3 → 6 (+3)
100% more capital invested
Capital invested by funds: $948K → $1.9M (+$947K)
8.13% more ownership
Funds ownership: 8.11% → 16.24% (+8.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$637K |
| 2 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
+$301K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$21.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$17.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$126 |
Top Sellers
CHNA Hedge Fund Activity: Q3 2020 in Review
6 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q3 2020, worth a combined $1.9M — up 100% from $948K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CHNA positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, adding an estimated $637K.
- 6 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q3 2020, up from 3 in Q2 2020.
- Funds reported $1.9M of Loncar China BioPharma ETF stock for Q3 2020, up 100% quarter-over-quarter.
- 3 funds opened new Loncar China BioPharma ETF positions in Q3 2020 and 0 closed out, a net change of +3 holders.
- The largest Loncar China BioPharma ETF buyer in Q3 2020 was Jane Street, an estimated $637K added.
Based on aggregated 13F filings for Q3 2020.